RET-altered Solid Tumors: Clinical Trials

1 completed, 1 recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 1, Recruiting 1
Phase 2	2	Completed 1, Recruiting 1

Follow RET-altered Solid Tumors: new trials by email Literature Review of RET-altered Solid Tumors trials Research Report on RET-altered Solid Tumors

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities TAS0953/HM06 - RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors	Phase 1 / Phase 2	Recruiting	Taiho Pharmaceutical Co., Ltd.	244	2020-12-16	2026-08-19
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer	Phase 1 / Phase 2	Completed	Hoffmann-La Roche	590	2017-03-17	2025-05-31

Narrower conditions

Adenocarcinoma (1)  ·  Adenocarcinoma, Papillary (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Carcinoma, Medullary (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colonic Diseases (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)

Broader conditions

Bronchial Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Multiple Endocrine Neoplasia (1)  ·  Neoplasms, Ductal, Lobular, and Medullary (1)  ·  Neoplasms, Multiple Primary (1)  ·  Neoplastic Syndromes, Hereditary (1)  ·  Rectal Diseases (1)

Interventions

pralsetinib (1)

Sponsors

Hoffmann-La Roche (1)  ·  Taiho Pharmaceutical Co., Ltd. (1)

Countries

South Korea (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Results publications

PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723

NIH funding

2016 (1)